• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Sionna Therapeutics Inc.

    4/29/25 7:31:12 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SION alert in real time by email
    DEFA14A 1 d946596ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    SIONNA THERAPEUTICS, INC.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table below in exhibit required by Item 25(b) Exchange Act Rules 14a-6(i)(14) and 0-11.

     

     
     


    LOGO

    Your Vote Counts! SIONNA THERAPEUTICS, INC. 2025 Annual Meeting Vote by June 11, 2025 11:59 PM ET SIONNA THERAPEUTICS, INC. 21 HICKORY DRIVE, SUITE 500 WALTHAM, MA 02451 V72401-P31556 You invested in SIONNA THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 12, 2025. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 29, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote Virtually at the Meeting* Point your camera here and June 12, 2025 10:00 AM EDT vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/SION2025 *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote on these important matters. Board Voting Items Recommends 1. To elect three class I directors to serve until our 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Nominees: For 01) Joshua Resnick, M.D., M.B.A. 02) Bruce Booth, D.Phil. 03) Lucian Iancovici, M.D. 2. To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the For fiscal year ending December 31, 2025. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any continuation, adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V72402-P31556

    Get the next $SION alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SION

    DatePrice TargetRatingAnalyst
    12/1/2025$24.00Sector Perform → Underperform
    RBC Capital Mkts
    11/19/2025$50.00Buy
    BTIG Research
    9/3/2025$45.00Strong Buy
    Raymond James
    9/3/2025$22.00Sector Perform
    RBC Capital Mkts
    3/4/2025Buy
    TD Cowen
    3/4/2025$32.00Buy
    Stifel
    3/4/2025$45.00Buy
    Guggenheim
    More analyst ratings

    $SION
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thompson Peter A. sold $1,379,866 worth of shares (30,953 units at $44.58) (SEC Form 4)

    4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

    2/4/26 7:43:55 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc sold $1,379,866 worth of shares (30,953 units at $44.58) (SEC Form 4)

    4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

    2/4/26 7:39:05 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Tpg Gp A, Llc sold $10,000,000 worth of shares (250,000 units at $40.00) (SEC Form 4)

    4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

    1/26/26 5:24:52 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SION
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tpg Gp A, Llc bought $950,400 worth of shares (60,000 units at $15.84) (SEC Form 4)

    4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

    7/1/25 5:03:20 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Tpg Gp A, Llc converted options into 4,875,547 shares and bought $20,250,000 worth of shares (1,125,000 units at $18.00) (SEC Form 4)

    4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)

    2/12/25 5:21:33 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SION
    SEC Filings

    View All

    SEC Form 144 filed by Sionna Therapeutics Inc.

    144 - Sionna Therapeutics, Inc. (0002036042) (Subject)

    11/24/25 8:22:56 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Sionna Therapeutics Inc.

    144 - Sionna Therapeutics, Inc. (0002036042) (Subject)

    11/21/25 4:24:21 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Sionna Therapeutics Inc.

    144 - Sionna Therapeutics, Inc. (0002036042) (Subject)

    11/21/25 4:21:36 PM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SION
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

    WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11th, 2026 at 2:00 p.m. ET. A live webcast of the presentation will be available under the "Events" page within the Investors section of Sionna's website at https://investors.sionnatx.com/. A replay will also

    2/4/26 7:00:00 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026 at 9:45 a.m. PT/12:45 p.m. ET. A live webcast of the presentation will be available under the "Events" page within the Investors section of Sionna's website at https://investors.sionnatx.com/. A replay will also be

    1/5/26 7:00:00 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sionna Therapeutics to Participate in Upcoming December Investor Conferences

    WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events: 8th Annual Evercore Healthcare Conference on Wednesday, December 3rd, 2025, at 12:30 p.m. ET; andCiti 2025 Global Healthcare Conference on Thursday, December 4th, 2025, at 9:45 a.m. ET Live webcasts of the presentations will be avail

    11/24/25 7:00:00 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SION
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sionna Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Sionna Therapeutics from Sector Perform to Underperform and set a new price target of $24.00

    12/1/25 8:19:04 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Sionna Therapeutics with a new price target

    BTIG Research initiated coverage of Sionna Therapeutics with a rating of Buy and set a new price target of $50.00

    11/19/25 8:58:53 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Sionna Therapeutics with a new price target

    Raymond James initiated coverage of Sionna Therapeutics with a rating of Strong Buy and set a new price target of $45.00

    9/3/25 8:39:08 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SION
    Financials

    Live finance-specific insights

    View All

    Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

    SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial Next trials to initiate in the second half of 2025 with topline data expected in mid-2026 Sionna to hold a conference call today at 8:00 a.m. ET WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revo

    6/4/25 7:00:00 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SION
    Leadership Updates

    Live Leadership Updates

    View All

    Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer

    WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the appointment of Caroline Stark Beer, MBA, as its Chief Business Officer (CBO). "We are delighted to welcome Caroline to our executive team at such a pivotal stage for Sionna," said Mike Cloonan, President and Chief Executive Officer of Sionna. "Caroline's exceptional experience, leadership, and value creation mindset will

    9/8/25 8:00:00 AM ET
    $SION
    Biotechnology: Pharmaceutical Preparations
    Health Care